|
ZEN003694 Clinical Trials
3 actively recruiting trials across 3 locations
Also known as: ZEN-3694
Pipeline
Phase 2: 3
Top Sponsors
- Zenith Epigenetics1
- Memorial Sloan Kettering Cancer Center1
- Alexander B Olawaiye, MD1
Indications
- Cancer3
- Peritoneal Cancer1
- Squamous Cell Lung Cancer1
- Metastatic Castration-resistant Prostate Cancer1
- Fallopian Tube Cancer1
Los Angeles, California1 trial
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
California Research Institute
Phase 2
Basking Ridge, New Jersey1 trial
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities
Phase 2
Pittsburgh, Pennsylvania1 trial
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
University of Pittsburgh Medical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.